Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q2 2026 · 10-Q
Revenue$327.32M$327.32M−5.3% vs Q2 2025 Net Income$38.68M$38.68M+14.3% vs Q2 2025 EPS Diluted$0.81$0.81+22.7% vs Q2 2025 Gross Profit$194,744,000+3.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$111,321,000+128.0% Free Cash Flowderived$106,305,000+169.9% Margins · derivedGross margin59.5%+5.2 pt vs Q2 2025
Operating margin17.9%+2.9 pt vs Q2 2025
Net margin11.8%+2.0 pt vs Q2 2025
ended Sep 27, 2025 · filed Nov 6, 2025 · 40 d after period end